PaulusWJTschöpeC. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol2013; 62: 263–271.
2.
MunzelTGoriTKeaneyJFJr, et al.Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. Eur Heart J2015; 36: 2555–2564.
3.
KohlhaasMNickelAGMaackC. Mitochondrial energetics and calcium coupling in the heart. J Physiol2017; 595: 3753–3763.
4.
AimoACastiglioneVBorrelliC, et al.Oxidative stress and inflammation in the evolution of heart failure: from pathophysiology to therapeutic strategies. Eur J Prev Cardiol. 2020; 27: 494–510.
5.
TsutsuiHKinugawaSMatsushimaS. Oxidative stress and heart failure. Am J Physiol – Heart Circ Physiol2011; 301: H2181–H2190.
6.
NickelAGvon HardenbergAHohlM, et al.Reversal of mitochondrial transhydrogenase causes oxidative stress in heart failure. Cell Metab2015; 22: 472–484.
7.
MannDL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res2015; 116: 1254–1268.
8.
LonnEBoschJYusufS, et al.HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer. ACC Curr J Rev2005; 14: 14–15.
9.
Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet1999; 354: 447–455.
10.
WannametheeSGBruckdorferKRShaperAG, et al.Plasma vitamin C but not vitamin E is associated with reduced risk of heart failure in older men. Circ Heart Fail2013; 6: 647–654.
11.
GivertzMMAnstromKJRedfieldMM, et al.Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the EXACT-HF study. Circulation2015; 131: 1763–1771.
12.
MonteroDLundbyC. Reduced arteriovenous oxygen difference in heart failure with preserved ejection fraction patients: is the muscle oxidative phenotype certainly involved?Eur J Prev Cardiol2017; 24: 1157–1160.
13.
MeirellesLRMatsuuraCde Castro ResendeA, et al.Chronic exercise leads to antiaggregant, antioxidant and anti-inflammatory effects in heart failure patients. Eur J Prev Cardiol2014; 21: 1225–1232.
14.
TouyzRM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?Hypertension2004; 44: 248–252.
15.
SteinbergDWitztumJL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis?Circulation2002; 105: 2107–2111.
16.
RidkerPMEverettBMThurenT, et al.CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med2017; 377: 1119–1131.
17.
EverettBMCornelJHLainscakM, et al.Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. Circulation2019; 139: 1289–1299.
18.
DaubertMAYowEDunnG, et al.Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide. Circ Heart Fail2017; 10: e004389–e004389.
19.
AbbateAVan TassellBWBiondi-ZoccaiG, et al.Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol2013; 111: 1394–1400.
20.
Van TassellBWBuckleyLFCarboneS, et al.Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2). Clin Cardiol2017; 40: 626–632.
21.
LaoutarisIDDritsasABrownMD, et al.Immune response to inspiratory muscle training in patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil2007; 14: 679–686.
22.
TsarouhasKKaratzaferiCTsitsimpikouC, et al.Effects of walking on heart rate recovery, endothelium modulators and quality of life in patients with heart failure. Eur J Cardiovasc Prev Rehabil2011; 18: 594–600.
23.
YangYBazhinAVWernerJ, et al.Reactive oxygen species in the immune system. Int Rev Immunol2013; 32: 249–270.
